title: Metabolomics and Metabolic Diseases: Where Do We Stand?
abstract: Metabolomics, or the comprehensive profiling of small molecule metabolites in cells, tissues, or whole organisms, has undergone a rapid technological evolution in the past two decades. These advances have led to the application of metabolomics to defining predictive biomarkers for incident cardiometabolic diseases and, increasingly, as a blueprint for understanding those diseases' pathophysiologic mechanisms. Progress in this area and challenges for the future are reviewed here.
authors.affiliation: Sarah W. Stedman Nutrition and Metabolism Center, Duke Molecular Physiology Institute, Departments of Pharmacology & Cancer Biology and Medicine, Duke University Medical Center, Durham, NC 27701, USA. Electronic address: chris.newgard@duke.edu.
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Newgard
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D008659:Metabolic Diseases / Q000378:metabolism*; D055442:Metabolome; D055432:Metabolomics; D008954:Models, Biological; D016896:Treatment Outcome
keywords: cardiovascular diseases; diabetes; metabolic diseases; metabolism; metabolomics; obesity